文献速递精神分裂症与精神病性障碍

首发精神病患者两年内谷氨酸水平与症状及认知相关

Cerebral glutamate levels over two years in initially antipsychotic-naïve first-episode patients with psychosis are related to clinical symptoms and cognition.
PubMed 文献 · Mol Psychiatry · 2025-09-15

该研究对57例未用药首发精神病患者和55名健康对照进行为期两年的随访,使用3T磁共振波谱测量背侧前扣带皮层和左侧丘脑的谷氨酸水平。发现患者背侧前扣带皮层谷氨酸较低且与注意力缺陷相关,丘脑谷氨酸较高与更明显的阳性症状相关,两年后丘脑谷氨酸与阴性症状正相关。

要点

  • 首发精神病患者背侧前扣带皮层谷氨酸较低,且与注意力缺陷相关。
  • 丘脑谷氨酸水平较高与更明显的阳性症状相关。
  • 两年后丘脑谷氨酸与阴性症状呈正相关。

核心结论

  • 首发精神病患者两年内背侧前扣带皮层谷氨酸较低与注意力缺陷相关。
  • 丘脑谷氨酸水平较高与更明显的阳性症状相关,两年后与阴性症状正相关。
  • 降低丘脑谷氨酸和升高背侧前扣带皮层谷氨酸的谷氨酸能药物可能对首发精神病有益。

研究设计与样本

  • 研究纳入57例最初未用药的首发精神病患者(年龄22.6±5.0岁,58%女性)和55名健康对照。
  • 在基线、6周、6个月和两年时使用3T磁共振波谱测量背侧前扣带皮层和左侧丘脑谷氨酸水平。
  • 使用线性混合模型分析谷氨酸水平与阳性症状、阴性症状及注意力/空间工作记忆认知测试的关系。

主要发现

  • 首发精神病患者背侧前扣带皮层谷氨酸水平较低(p=0.03),且在所有访视点与注意力缺陷相关(p<0.05)。
  • 丘脑谷氨酸水平组间无差异,但较高水平与所有访视点更明显的阳性症状相关(p=0.02)。
  • 丘脑谷氨酸与阴性症状的关系随时间变化(阴性症状*时间:p=0.003),两年时呈显著正相关(p=0.04),其他访视点无显著关联。
  • 丘脑NAA在首发精神病患者中较低(p=0.04),总肌酸在治疗6周后升高(p=0.01),背侧前扣带皮层Glx在两年后较低(p=0.02)。

临床怎么用

  • 在首发精神病最初两年内,评估丘脑谷氨酸水平可能有助于理解阳性症状严重程度。
  • 背侧前扣带皮层谷氨酸水平较低可能与注意力缺陷相关,提示认知评估可结合谷氨酸测量。
  • 谷氨酸能化合物治疗策略或需考虑降低丘脑谷氨酸和升高背侧前扣带皮层谷氨酸。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although emerging evidence supports glutamatergic dysfunction in schizophrenia, clinical trials with glutamatergic compounds have overall been negative. This may be due to changes in glutamate levels during the course of illness. To address this, we measured glutamate levels in dorsal anterior cingulate cortex (dACC) and left thalamus in 57 initially antipsychotic-naïve patients with first-episode psychosis (FEP) aged 22.6 ± 5.0 years (58% females) and 55 healthy controls (HC) on a 3T MR scanner at baseline, after six weeks (48 FEP and 53 HC), six months (37 FEP and 49 HC), and two years (35 FEP and 45 HC). Positive and negative symptoms and cognitive function in tests of attention and spatial working memory were assessed at all visits. Linear mixed models were used in statistical analyses. We found lower glutamate levels in dACC in FEP (p = 0.03) that was associated with deficits in attention at all visits (p < 0.05). Thalamic glutamate levels did not differ between groups, but higher levels were related to more pronounced positive symptoms at all visits (p = 0.02). The relation between thalamic glutamate levels and negative symptoms was altered over time (negative symptoms*time: p = 0.003) due to a significant positive association after two years (p = 0.04) but not at other visits. For other metabolites, thalamic NAA were lower in FEP (p = 0.04) and total creatine was increased after 6 weeks treatment (p = 0.01), whereas dACC glx levels were lower after two years (p = 0.02). The results suggest that greater positive symptom severity is related to higher thalamic glutamate levels and cognitive deficits to lower dACC glutamate levels during the first two years of illness. Furthermore, higher thalamic glutamate levels after two years are associated with more severe negative symptomatology. Findings imply that glutamatergic compounds decreasing thalamic and increasing dACC glutamate levels may be beneficial in FEP over the first two years of illness.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bojesen KB, Lemvigh CK, Sigvard AK, et al. Cerebral glutamate levels over two years in initially antipsychotic-naïve first-episode patients with psychosis are related to clinical symptoms and cognition. Mol Psychiatry. 2025. PMID: 40954276. doi:10.1038/s41380-025-03234-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。